Efficacy and safety of the use of alirocumab in real clinical practice

CONCLUSION: The inclusion of alirocumab in the treatment regimen contributed to the stable course of atherosclerosis-associated diseases, the achievement of LDL cholesterol targets in 77.8% of patients, was not accompanied by side effects during 2.5 years therapy.PMID:37167185 | DOI:10.26442/00403660.2022.12.201991

Source: Atherosclerosis - May 11, 2023 Category: Cardiology Authors: V A Korneva T Y Kuznetsova I S Scopets N N Vezikova Source Type: research